This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Weiterführende Literatur zu Kap.11
Bolte HD (1996) Entzündliche Herzerkrankungen und Kardiomyopathien. In: Erdmann E, Rieker G (Hrsg.) Klinische Kardiologie. Springer, Berlin Heidelberg New York, S 194–308
Braunwald E, Morrow AG, Cornell WP et al. (1960) Idiopathic hypertrophic subaortic stenosis: hemodynamic and angiographic manifestations. Am J Med 29:924–945
Bonow RO, Rosing DR, Bacharach SL et al. (1981) Effects of verapamil on left vntricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64: 787–796
Caforio ALP, Goldman JH, Haven AJ et al. (1997) Circulating cardiac autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. Eur Heart J 18:270–275
Cohen J, Effat H, Goodwin JF et al. (1964) Hypertrophic obstructive cardiomyopathy. Br Heart J 26:16–32
Figulla, HR, Gietzen F, Zeymer U et al. for the DiDi Study Group (1996) Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 94:346–352
Friart A, Stamatakis L, Philippart C (1990) Doppler evaluation of left ventricular filling: effect of verapamil on non-obstructive hypertrophic cardiomyopathy. Eur Heart J 11:839–844
Hanrath P, Mathey DG, Siegert R, Bleifeld W (1980) Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: and echocardiographic study. Am J Cardiol 45:15–23
Hopf R, Kaltenbach M (1987) 10-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists. Z Kardiol 76 (Suppl 3): 137
Hopf R, Kaltenbach M (1987) Effects of nifedipine and propranolol combined therapy in patients with hypertrophic cardiomyopathy. Z Kardiol 76 (Suppl 3): 105–112
Kaltenbach M, Hopf R, Keller M (1976) Calciumantagonistische Therapie bei hypertrophobstruktiver Kardiomyopathie. Dtsch Med Wochenschr 101:1284–1287
Kaltenbach M, Hopf R, Kober G et al. (1979) Treatment of hypertrophie obstructive cardiomyopathy with verapamil. Br Heart J 42:35–42
Kober G, Hopf R, Biamino G et al. (1987) Long-term treatment of hypertrophie cardiomyopathy with verapamil or propranolol in matched pairs of patients: Results of a multicenter study. Z Kardiol 76 (Suppl 3): 113–118
Kron J, Oliver RP, Norsted S, Silka MJ (1990) The automatic implantable cardioverterdefibrillator in young patients. J Am Coll Cardiol 16:896
Kuhn H, Thelen U, Leuner C et al. (1980) Langzeitbehandlung der hypertrophischen nicht obstruktiven Kardiomyopathie (HNCM) mit Verapamil. Z Kardiol 69:669
Kunkel B, Schneider M, Eisenmenger A et al. (1987) Myocardial biopsy in patients with hypertrophic cardiomyopathy: Correlations between morphologic and clinical parameters and development of myocardial hypertrophy under medical therapy. Z Kardiol 76 (Suppl 3): 33–38
Lemke R, Kaltenbach M (1987) Systolic anterior movement of the mitral valve and the Venturi effect: an in vitro study. Z Kardiol 76 (Suppl 3): 87–90
Maron BJ, Epstein SE (1979) Hypertrophie cardiomyopathy: A discussion of nomenclature. Am J Cardiol 43:1242–1244
Maron BJ, Merrill WH, Freier PA et al. (1978) Longterm clinical course and symptomatic status of patients after operation for hypertrophie subaortic stenosis. Circulation 57:1205
Pelliccia F, Cianfrocca C, Romeo F, Reale A (1990) Hypertrophie cardiomyopathy: Long-term effects of propranolol versus verapamil in preventing sudden death in “low-risk” patients. Cardiovasc Drugs Ther 4:1515–1518
Richardson P, McKenna WJ, Bristow M et al. (1996) Report of the 1995 World Organization/ International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841–842
Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 60:1201–1207
Schulte HD, Bircks W, Löse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM). Z Kardiol 76 (Suppl 3): 145
Seiler C, Hess OM, Turina J et al. (1989) Langzeitverlauf der hypertrophen Kardiomyopathie: medikamentöse versus operative Therapie. Schweiz med Wochenschr 119:1511
Shaffer EM, Rocchini AP, Spicer RL et al. (1988) Effects of verapamil on left ventricular diastolic filling in children with hypertrophic cardiomyopathy. Am J Cardiol 61:413–417
Teare RD (1958) Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20:1–8
ten Cate FJ (1985) Hypertrophic cardiomyopathy — Clinical recognition and management. Delcker, New York Basel
Watkins H, Rosenzweig A, Hwang DS et al. (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326: 1108
Wigle FD, Heimbecker RO, Gunton RW (1962) Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation 26: 325–340
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kaltenbach, M. (2000). Herzmuskelerkrankungen. In: Kaltenbach, M. (eds) Kardiologie kompakt. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57728-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-57728-4_11
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-7985-1153-8
Online ISBN: 978-3-642-57728-4
eBook Packages: Springer Book Archive